Suchergebnisse - "Cervantes, A"

PubPharm (23)

1

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

enthalten in: Scientific reports | 2019

von Borrero-Palacios, A. | Cebrián, A. | Gómez Del Pulgar, M. | +21

ErratumIn: Sci Rep. 2019 May 17;9(1):7706. - PMID 31097738

2

PAN-EX : a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2016

von Sclafani, F. | Brown, G. | Cunningham, D. | +13

3

Phase II study of necitumumab plus modified FOLFOX6 as first-line treatment in patients with locally advanced or metastatic colorectal cancer

enthalten in: British journal of cancer | 2016

von Elez, E. | Hendlisz, A. | Delaunoit, T. | +6

4

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer : results of the EXPERT-C trial

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2015

von Sclafani, F. | Chau, I. | Cunningham, D. | +16

5

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer

enthalten in: British journal of cancer | 2015

von Macarulla, T. | Cervantes, A. | Tabernero, J. | +10

6

HER2 in high-risk rectal cancer patients treated in EXPERT-C, a randomized phase II trial of neoadjuvant capecitabine and oxaliplatin (CAPOX) and chemoradiotherapy (CRT) with or without cetuximab

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2013

von Sclafani, F. | Roy, A. | Cunningham, D. | +9

7

Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer

enthalten in: European journal of cancer (Oxford, England : 1990) | 2013

von Gonzalez-Martin, A. | Gladieff, L. | Tholander, B. | +62

CommentIn: Eur J Cancer. 2014 Mar;50(4):862-3. - PMID 24418723

8

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy : results of a phase II single institution trial

enthalten in: British journal of cancer | 2008

von Martín-Martorell, P. | Roselló, S. | Rodríguez-Braun, E. | +3

9

Randomized phase II trial of carboplatin versus paclitaxel and carboplatin in platinum-sensitive recurrent advanced ovarian carcinoma : a GEICO (Grupo Espanol de Investigacion en Cancer de Ovario) study

enthalten in: Annals of oncology : official journal of the European Society for Medical Oncology | 2005

von González-Martín, A. | Calvo, E. | Bover, I. | +13

10

A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer

enthalten in: Gynecologic oncology | 2004

von Clamp, A. | Adams, M. | Atkinson, R. | +8